Deals
Teva Struggle to Grow Explains Urgency of Face-Off With Mylan
This article is for subscribers only.
How desperately does Teva Pharmaceutical Industries Ltd. need an acquisition to help it grow?
Investors will get a clue today. The world’s largest generics-drugmaker will probably report its third consecutive drop in quarterly revenue, according to analyst estimates compiled by Bloomberg. With competition looming this year for its $4.2 billion Copaxone drug, Petach Tikva, Israel-based Teva’s $40.1 billion offer for Mylan NV, which has already been rebuffed, highlights the company’s desire to expand.